Author/Authors :
Dedinská, Ivana Surgery Clinic and Transplant Center - University Hospital Martin and Jessenius Faculty of Medicine Comenius University, Martin, Slovakia , Svetlík, Daniel Dialysis Center Logman AS, Žilina , Adamicová, Katarína Department of Pathology - University Hospital Martin and Jessenius Faculty of Medicine Comenius University, Martin, Slovakia , Macháleková, Katarína BB Biocyt - Banská Bystrica, Slovakia , Makovický, Pavel Clinic of Internal Medicine I - University Hospital Martin and Jessenius - Faculty of Medicine - Comenius University, Martin, Slovakia , Ježíková, Alena Clinic of Internal Medicine I - University Hospital Martin and Jessenius - Faculty of Medicine - Comenius University, Martin, Slovakia , Laca, Ľudovít Surgery Clinic and Transplant Center - University Hospital Martin and Jessenius Faculty of Medicine Comenius University, Martin, Slovakia , Miklušica, Juraj Surgery Clinic and Transplant Center - University Hospital Martin and Jessenius Faculty of Medicine Comenius University, Martin, Slovakia , Galajda, Peter Clinic of Internal Medicine I - University Hospital Martin and Jessenius - Faculty of Medicine - Comenius University, Martin, Slovakia , Mokáň, Marián Clinic of Internal Medicine I - University Hospital Martin and Jessenius - Faculty of Medicine - Comenius University, Martin, Slovakia
Abstract :
Treatment of retroperitoneal fibrosis usually involves corticosteroids
with or without other immunomodulating medications or
tamoxifen. Rituximab, a monoclonal antibody that specifically
targets CD20 on the surface of B cells, is effective in achieving
complete remission of proteinuria in patients with idiopathic
membranous nephropathy. We describe a case of a 45-year-old man
with idiopathic membranous glomerulonephritis and proteinuria
and simultaneously with idiopathic retroperitoneal fibrosis (with
a large number of CD20 cells in the histologic image). The patient
did not tolerate the treatment with cyclophosphamide, and as
rescue therapy, administration of rituximab was indicated with
excellent effect. We recorded prompt reduction of proteinuria
and significant reduction of retroperitoneal fibrosis. Rituximab is
effective in the treatment of idiopathic retroperitoneal fibrosis with
positivity of CD20 cells, as well as in the treatment of idiopathic
membranous glomerulonephritis.
